Post Test

CME

The post-test is included for your review

To receive complimentary CME credit, take the post-test online athttp://cme-online.med.upenn.edu

The program is available for CME credit through August 31, 2005.

Accreditation and Credit Designation

The University of Pennsylvania School of Medicine is accredited bythe Accreditation Council for Continuing Medical Education(ACCME) to provide continuing medical education for physicians.

The University of Pennsylvania School of Medicine designates this educational activity for a maximumof 1 Category 1 credit toward the AMA Physician's Recognition Award. Each physician shouldclaim only those credits that he/she actually spent in the activity.

CE

The post-test is included for your review

To receive complimentary CE credit, take the post-test online athttp://www.pharmacytimes.com/inflammation

Accreditation and Credit Designation

Pharmacy Times

is accredited by the Accreditation Council for Pharmacy Educationas a provider of continuing pharmaceutical education.

This program is approved for 1 contact hour (0.1 CEU) under the ACPE universalprogram number of 290-999-04-029-HO1. The program is available for CE creditthrough August 31, 2005.

Post-Test

1. Clinical features of metabolic syndrome(MetSyn) include all of the following except _______.

1. hypothyroidism
2. insulin resistance
3. atherogenic dyslipidemia
4. hypertension

2. The current American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association panel criterionfor glucose in the diagnosis of MetSyn is ______.

1. random glucose ≥160 mg/dL
2. random glucose ≥160 mg/dL and abnormal oral glucose tolerance test (OGTT)
3. fasting glucose ≥115 mg/dL and abnormal OGTT
4. fasting glucose ≥100 mg/dL or abnormal OGTT

3. Which patient fulfills the diagnostic criteria forMetSyn?

1. A man with waist of 41 inches, triglycerides of 160 mg/dL, and blood pressure of 136/86mm Hg.
2. A man with waist of 38 inches, high-densitylipoprotein (HDL) cholesterol of 40 mg/dL, and blood pressure of 160/94 mm Hg.
3. A woman with waist of 36 inches, HDL cholesterol of 52 mg/dL, and fasting glucose of118 mg/dL.
4. A woman with triglycerides of 162 mg/dL, blood pressure of 132/80 mm Hg, and fastingglucose of 120 mg/dL.

4. The prevalence of MetSyn is ______.

1. roughly equal to the age of the population of interest
2. higher in black men than in white men
3. higher in Mexican American women than in Asian women
4. all of the above

5. Which statement is true concerning the risk ofprogression to type 2 diabetes or coronaryheart disease (CHD) in patients with MetSyn?

1. In the West of Scotland Coronary Prevention Study (WOSCOPS), the risk of progressionto type 2 diabetes was 50% higher in patients with MetSyn than in those without MetSyn.
2. In WOSCOPS, the risk of progression to type 2 diabetes was 24 times higher inpatients with at least 4 of the components of MetSyn than in those without MetSyn.
3. In a meta-analysis of European trials, the hazard ratio for CHD mortality in patientswith MetSyn was 5 to 6 compared with those without MetSyn.
4. In the Kuopio Ischaemic Heart Disease Risk Factor Study, CHD mortality was 7 times higher in men with MetSyn than in men without MetSyn.

6. Medications associated with an increased riskfor MetSyn include all of the following except ______.

1. corticosteroids
2. antipsychotics and antidepressants
3. cholinesterase inhibitors
4. protease inhibitors for human immunodeficiency virus infection

7. In patients with atherogenic dyslipidemia,statins are most effective in ______.

1. reducing triglycerides
2. reducing low-density lipoprotein (LDL) cholesterol
3. elevating HDL cholesterol
4. elevating the ratio of LDL cholesterol to triglycerides

8. The most likely to improve combination hightriglycerides and low HDL cholesterol would be ______.

1. a statin and insulin
2. a statin or a fibrate
3. a statin and an oral hypoglycemic
4. a fibrate and niacin

9. Which of the following types of antihypertensiveagent is associated with the greatest risk ofprogression to type 2 diabetes in patients with MetSyn?

1. Calcium channel blocker
2. Beta blocker
3. Angiotensin-converting enzyme inhibitor
4. Angiotensin receptor blocker

10. To reduce thrombotic risk associated withMetSyn, aspirin is recommended in ______.

1. MetSyn patients whose 10-year risk for CHD is ≥10%
2. only those MetSyn patients with clinical or laboratory evidence of venous thrombosis
3. only those MetSyn patients with elevated inflammatory markers
4. all MetSyn patients